The five main barriers for Orphan Drugs in Asia Pacific are (1) Market complexity (2) Regulatory strategy (3) Pharmaco-vigilance (4) Ethical marketing and (5) Access to skilled regional management. This article focuses on the area of regulatory strategy. ..
Welcome to AFT Orphan
AFT Pharmaceuticals is a privately owned company with operations in Australia and New Zealand with a developing organisation in South East Asia (based out of its regional office in Kuala Lumpur, Malaysia). The company was founded in 1997 by Dr Hartley Atkinson.
The vision of AFT Orphan is to be the leading company in Asia, Australia and New Zealand providing access to orphan medicines for patients suffering from rare diseases.
AFT Orphan Mission
Giles Moss |
- Provide a low risk and cost effective solution for Biotech companies with commercialised Orphan Drugs to access Asia, Australia and New Zealand.
- To leverage established infrastructure and widespread industry expertise to ensure rapid patient and physician access to important life changing therapies.
- To built custom solutions for the ethical medical promotion of orphan drugs which could include central teams operating at the regional key opinion leader level or more involved individual country sales organisations.
- To be transparent, providing reassurance to partners that promotion will be ethical and backed by best in class operations, supply chain and pharmaco-vigilance.
The AFT Orphan competitive advantage is that we can leverage a unique depth of functional experience within the team. With fully established capabilities in research and development, clinical trial database management (patient registries), regulatory, supply chain and pharmaco-vigilance we provide the ideal base to build a bespoke medical/marketing organisation to maximise orphan success across the region.
For Orphan Business Development enquiries please email giles@aftpharm.com or call +60193725670.
AFT Orphan Blog
There are five main barriers (Regulatory covered this time) which reduce access for Orphan Drugs in Asia Pacific
Monday, February 20, 2012
Featured Posts
View More Posts >>
- There are five main barriers (Regulatory covered this time) which reduce access for Orphan Drugs in Asia Pacific 20-Feb-2012
- There are five main barriers for Orphan Drugs in Asia Pacific 26-Jan-2012
- China is changing its attitude to Orphan Drugs 03-Jan-2012
- Expanding patient access for Orphan Drugs in Asia Pacific 12-Dec-2011
Tweet
